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ABSTRACT 
Aims and objectives 
This study sought to determine the relationship between health related quality of life 
(HRQoL), fatigue and activity levels of people with anaemia secondary to chronic kidney 
disease (CKD) over a 12 month period following the introduction of an erythropoietin 
stimulating agent (ESA). 
 
Background 
CKD occurs in five stages and it is a complex chronic illness which severely impacts on an 
individual’s HRQoL, and ability to perform everyday activities. Fatigue is also a common 
symptom experienced by people with CKD.  
 
Design and methods  
Using a longitudinal repeated measures design, 28 people with CKD completed the SF-36, 
human activity profile and fatigue severity scale at the commencement of an ESA and then at 
3, 6 and 12 months. 
 
Results  
Over a 12 month period, people reported a significant change in HRQoL in relation to role 
physical, vitality, mental health/emotional well-being and overall mental health. However 
activity levels did not significantly improve during that time.  Both the amount of 
breathlessness and level of fatigue were highest at baseline and declined over time. Both 
fatigue and breathlessness were correlated with less reported general health over time. 
 
Conclusion 
Renal nurses, in dialysis units and CKD outpatient clinics, have repeated and frequent contact 
with people with CKD over long periods of time, and are in an ideal position to routinely 
assess fatigue and activity levels and to institute timely interventions. Early detection would 
enable timely nursing interventions to optimise HRQoL and independent activity. 
 
Relevance to Clinical Practice 
Drawing on rehabilitation nursing interventions could assist renal nurses to minimize the 
burden of fatigue and its impact on simple everyday activities and a person’s quality of life.  
These interventions are important for people who are living at home and could assist in 
lowering the burden on home support services.  
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INTRODUCTION 
Chronic kidney disease (CKD) is rapidly increasing globally (Zhang & Rothenbacher 2008), 
and is predicted to  affect 11.5% of the adult population (23 million people) in the United 
States (Coresh et al. 2011), and other countries have detailed similar or higher prevalence 
estimates (AIHW 2009, White et al, 2010).  CKD is classified into five stages of severity, 
with stage 5 also referred to as end stage kidney disease (ESKD) where survival may be 
dependent on renal replacement therapy (dialysis & transplantation) (Vassalotti et al. 2007). 
No matter what the stage of CKD, people experience a range of symptoms that affect all body 
systems (Murtagh et al. 2007), and they are required to invest considerable time in managing 
their health, including modifying their diet, managing numerous medications, undergoing 
renal replacement therapies (if required) and attending medical and hospital appointments. 
CKD, its treatment and concomitant complications also impact significantly on a person’s 
lifestyle, family responsibilities, their ability to work, and financial status. The impact of 
CKD and its treatment on physical, emotional, social and overall HRQoL is, therefore, 
profound.  
 
At least 45% of people with CKD, particularly those who are in stages 4 and 5, develop 
anaemia (Gandra et al. 2010). According to Lasch, Evans and Schatell (2009) people with 
anaemia due to CKD commonly report decreased energy, tiredness, shortness of breath and 
weakness. In addition, anaemia in CKD contributes to significant co-morbid complications 
such as left ventricular hypertrophy, congestive heart failure, and ischaemic heart disease 
(Brattich 2007, Schimid & Schiffl 2010). As a consequence, people have increased 
hospitalizations and a shorter life expectancy (Palmer et al. 2010, Voormolen et al. 2010). An 
erythropoietin stimulating agent (ESA) is frequently prescribed to increase haemoglobin 
levels in order to reduce these complications (Rathi et al. 2010, Schmid & Schiffl 2010, 
Mikhail et al. 2011).  In addition there is some evidence to suggest that increasing 
haemoglobin levels from between 110 to 120 g/L (11-12 g/dl) in people with CKD stages 3-5 
will lead to improvements in patient reported HRQoL (Finkelstein et al. 2009, Hansen et al. 
2009).  
 
BACKGROUND 
Fatigue and CKD   
Fatigue is a complex, subjective experience (McCann & Boore 2000) and is reported  by 70-
97% of people with CKD (Murtagh et al. 2007, Jhamb et al. 2008, Bossola et al. 2011).  
Despite advances in renal health care, fatigue remains ranked as one the most troublesome 
symptoms for people with CKD (Danquah et al. 2010). Factors associated with the fatigue 
experienced in CKD include: prescribed medications and their side effects; nutritional 
deficiencies; physiological alterations, particularly abnormal urea and haemoglobin levels; 
psychological factors such as depression, sleep dysfunction and those associated with 
haemodialysis treatment (low dialysate sodium and excessive ultrafiltration) (Welch 2006). 
Fatigue has been extensively examined, particularly in haemodialysis patient populations 
(McCann & Boore 2000, Jablonski 2007, Danquah et al. 2010). Not surprisingly fatigue due 
to CKD has a considerable effect on a person’s HRQoL and is viewed as being more 
important than survival by some patients (Jhamb et al. 2008).  Using the fatigue severity 
scale, Bonner et al. (2008) found people with varying stages of CKD who were prescribed an 
ESA for anaemia reported higher fatigue levels than those who were not prescribed an ESA. 
These findings provided the impetus for this study.   
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Activity and CKD 
There is a reduced capacity of people with CKD to engage in activities of daily living 
including exercise activity (Bonner et al. 2009, White et al. 2009) which is likely to be due to 
a number of factors including anaemia, fatigue, lengthy treatment commitments, and 
debilitating co-morbid conditions.  While ESA has profoundly improved the potential for 
higher activity levels in people with CKD (Painter et al. 2002, Gandra et al. 2010) there has 
not been a corresponding increase in activity levels amongst this population (Painter et al. 
2011). Increasingly the promotion of activity including exercise programs has been argued as 
an integral component of rehabilitation programs towards the optimisation of health for 
people with CKD (Kosmadakis et al. 2010). While there have been some reports of 
successful increase in levels of activity, there has been little adoption of these interventions 
into routine nursing care (Bennett et al. 2010). Although there are several methods to 
measure activity and/or exercise capacity in people with CKD (Koufaki & Kouidi 2010), the 
Human Activity Profile (HAP), developed by Fix and Daughton (1988) has been 
demonstrated to be a valid and reliable instrument for assessing the levels of human activity 
(Wellard 2003, Davidson & de Morton 2007, Bonner et al. 2009).  
 
Health Related Quality of Life and CKD  
It is no longer adequate to measure only morbidity and mortality associated with chronic 
disease; HRQoL is particularly important in determining health outcomes for people with 
CKD (Soni et al. 2010).  Survival is longer in people with a better HRQoL, and better health 
status and less morbidity are associated with higher HRQoL (Untas et al. 2011).  There are 
several instruments available for measuring HRQoL in people with CKD, and the Medical 
Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the Kidney Disease Quality 
of Life [KDQOL], a renal specific version of the SF-36, are the most frequently used (Lowrie 
et al. 2003, Unruh et al. 2005). Finkelstein et al. (2009) used the KDQOL to examine the 
relationship between different haemoglobin levels and HRQoL in 1200 people with CDK 
stages 3-5, and reported that greater improvements in quality of life occurred when 
haemoglobin levels were higher. Using the SF-36, Hamilton and Hawley (2006) found that a 
nurse-led anaemia clinic for patients with CKD significantly improved levels of quality of 
life three to six months later.  
 
Surprisingly the relationship between haemoglobin, HRQoL and fatigue levels and their 
impact on actvity levels has not been reported. Given the increasing involvement of nurses in 
the aggressive symptom management of people with CKD, particularly as Nurse Practitioners 
(Holcomb 2005, Douglas & Bonner 2011), nursing research examining HRQoL, activity and 
fatigue is warranted. This is important for renal units where nursing roles are expanding to 
include advanced practice functions. In addition, increased knowledge about these health 
indicators has the potential to guide the development of nurse-led interventions specifically 
targeted at early symptom identification and management.  
 
STUDY 
The aims of this study were to: 
 Determine the HRQoL, activity and fatigue levels of people with anaemia secondary to 
CKD. 
 Compare HRQoL, activity and fatigue levels of people with anaemia secondary to CKD 
and in normal healthy population. 
 Determine the changes in HRQoL, activity and fatigue over twelve months following the 
introduction of ESA. 
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METHODS 
A longitudinal repeated measures design was used to assess HRQoL, current levels of activity 
and fatigue in people with CKD over a twelve month period. Data was collected from patient 
hospital records and measured by self-report questionnaires.  
 
Sample 
A convenience sample of patients was recruited from two renal units in Australia; one in 
Queensland and the other in New South Wales. The inclusion criteria for the study were: 1) 
patients 18 years of age or older; 2) CKD with an estimated glomerular filtration rate < 
60ml/min/1.72m
2
 (i.e. stages 3-5) with a haemoglobin <100g/L; 3) prescribed an ESA by a 
nephrologist; 4) able to understand English; and 5) willing to give informed consent and 
participate in the study.  There were no specific exclusion criteria. 
 
Ethical considerations 
Human Research Ethics Committees at both hospitals and a university provided ethical 
approval for the study. Signed informed consent was obtained from all participants prior to 
commencement of the study. 
 
Instruments 
Three instruments were used to measure HRQoL, activity and fatigue.  HRQoL was 
measured by the SF-36 (Ware 2011) which gives scores on eight scales, and which then form 
the two summary measures of physical health and mental health. The scales within the 
physical health summary measure are physical functioning, role-physical, bodily pain and 
general health.  The mental health summary measure consists of the following scales: vitality, 
social functioning, role-emotional and mental health/emotional well-being. Reliability in the 
present study for the individual scales ranged from a Cronbach alpha of .54 (general health) 
to .72 (mental health/emotional well-being) to .91 (role physical; bodily pain), and .93 
(physical functioning; role emotional).  
 
The Human Activity Profile (HAP) developed by Fix and Daughton (1988) is a self-report 
instrument comprising 94 items of daily activity ordered according to metabolic demand (e.g. 
sitting, walking, dressing, running etc); it requires respondents to indicate which activities 
they still undertake, those they have stopped doing and those they have never undertaken. 
The HAP has four activity subscales: Self-care, Personal/Household work, Entertainment/ 
Social, Independent exercise. The subscales had high reliability in the current study as 
evidenced from the following Cronbach alphas: Self-care (= .98), Personal/Household work 
(=.97), Entertainment/Social (=.92), Independent exercise ( =.94).  The dyspnoea scale 
(DS) consists of 8 items in which respondents indicate either no, little, clearly noticeable or 
severe shortness of breath when undertaking physical activity.  The reliability for the DS was 
.80.  
 
Lastly, fatigue was measured by the fatigue severity scale (FSS), a 9 item self-report 
instrument which requires respondents to indicate on a 7-point Likert scale the degree of 
agreement with the statement (Krupp et al. 1989). The FSS in the current study had a high 
reliability with a Cronbach alpha coefficient of .88.  
 
Data Collection 
After consenting, the following data were collected at 0 (immediately prior to commencing 
an ESA), and then at 3, 6 and 12 months. A review of a person’s medical records yielded: 1) 
demographic information (age and gender); 2) biochemistry and haematology results 
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(including haemoglobin, calcium, phosphate, potassium, urea, creatinine, albumin, 
parathyroid levels, iron studies, B12 & red cell folate); and 3) ESA therapy. At each time 
point, the questionnaires were provided to each participant by a member of the research team.  
If required, participants received assistance with completion of the questionnaires by one of 
the research team. Assistance was needed for participants with limited literacy, poor visual 
acuity or with restricted movement related to dialysis equipment. Questionnaire items were 
read aloud and response options sought.  
 
Analysis 
Data were analysed using SPSS Version 19
®
 (SPSS Inc., Chicago, IL, USA). Within-subjects 
analysis of variance (ANOVA) was used to measure HRQoL, fatigue and activity levels of 
patients with CKD at commencement of ESA, and then at 3, 6 and 12 months later, as the 
means tested are derived from repeated measurements. HRQoL, fatigue and activity levels 
were assessed in relation to demographics using t-tests and ANOVA. Probability (p) values 
less than 0.05 were considered significant. 
 
RESULTS 
Of the 28 patients with CKD initially in the study, five became deceased during the time of 
the research, two withdrew and one was lost to follow-up. Data were collected at 4 time 
points – baseline, 3 months, 6 months and 12 months. Baseline data were available for 28 of 
the patients. Table 1 indicates the number of patients at each time period.  Of the longitudinal 
sample, 15 were female and 13 were male. Age ranged from 31 to 84 years (mean = 64 
years).  23 patients were not yet receiving renal replacement therapy; 4 were receiving 
haemodialysis and 2 patients were receiving peritoneal dialysis. At baseline, haemoglobin 
levels ranged from 75 to 106 g/L (mean = 94 g/L). 
 
Table 1 Number of patients at each time period 
Baseline 3 months 6 months 12 months 
28  26  21  19 
 
Differences of HRQoL, activity, fatigue and breathlessness over time 
Table 2 provides the means and standard deviations across time for each of the SF-36 scales 
and the two summary measures (CKD sample). The population norms (normative sample) for 
each of the SF-36 scales also appear in Table 2. The SF-36 uses norm-based scoring with 
linear transformation of scores to a mean of 50 and a standard deviation of 10 (Ware, 2011). 
The CKD sample have much lower physical functioning, role-physical and general health 
compared to the normative sample of healthy adults. Bodily pain and overall physical health 
summary was comparable to the normative sample. For the emotional well-being scales, the 
CKD sample was lower on the vitality and social functioning scores than the normative 
sample. For the role-emotional subscale, the CKD sample was lower than the normative 
sample only at baseline. For the mental health subscale, the CKD sample was higher than the 
normative sample at 6 and 12 months. For the overall mental summary component, the CKD 
sample was higher than the mean of 50. 
 
Several one-way repeated measures ANOVAs were used to  measure whether there were 
changes over time in the SF-36 component scores (physical health, mental health) and each 
of the subscales of the SF-36, these being physical functioning, role physical, bodily pain, 
general health, vitality, social functioning, role-emotional and  mental health. There was a 
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significant improvement over time for the role physical, vitality and mental health subscales. 
Results of the repeated measures ANOVA also appear in Table 2.  
 
Question 1 (Q1) from the SF-36  (‘In general would you say your health is excellent, very 
good, good, fair or poor’) is often used as a reliable indicator of a person’s overall quality of 
life (Ware 2011). Table 3 shows the correlation between SF-36 Q1 and total physical activity, 
HAP subscale scores, fatigue and breathlessness at each time point. Total number of physical 
activities still being done correlated positively with reported health at 6 months. Self-care did 
not correlate significantly with responses on the SF-36 Q1 at any time point. Responses to 
general health correlated with personal/household work at baseline and at 3 months. People 
with CKD who engaged in these activities reported good health generally. The level of 
general health also correlated with reported entertainment/social activity at baseline, 3 and 6 
months, indicating that those who are able to do these activities report good health. 
Independent exercise was correlated with responses on the SF-36 Q1 only at baseline, 
indicating those engaging in fewer exercise activities also reported poorer general health. 
Breathlessness as measured by the dyspnoea subscale was correlated with lower reported 
general health over time.  Higher levels of fatigue were (negatively) correlated with lower 
health in general at each time point and this was significant at 3, 6 and 12 months. Finally 
using repeated Measures ANOVA,  to examine reported differences in general health over 
time, did not find any significant  differences [F(3,12)=.626, n.s.]. 
 
The HAP total activity and each subscale’s mean and standard deviation are summarized in 
Table 4.  The CKD sample engaged in considerably less physical activities across all time 
periods compared to healthy adults. While 100% of the normative sample were walking ½ 
block uphill (Fix & Daughton 1988), only 51.8% of the CKD sample was doing this activity 
at baseline, and by 12 months this had dropped to 44.4% still walking ½ block uphill. 
Similarly walking 1 block on level ground, non-stop by the CKD sample also dropped from 
62.5% at baseline to 44.4% at 12 months, compared to 100% of normal adults doing this 
activity. Only 13.4% of the CKD sample could climb steps (2 1/2 floors) at baseline 
compared to 84.2% of normal adults. By 6 months this had dropped to only 7.4% of the renal 
sample still engaging in this physical activity. The CKD sample was similar to the normative 
sample in self-care activities. Across all time points the CKD sample engaged in considerably 
less personal/household work and entertainment/social activities compared to healthy adults. 
The activities which appeared to distinguish between people with CKD and healthy adults the 
most were independent exercise activities. Normal adults engaged in three times more of 
these activities compared to the CKD sample.  
 
A repeated measures ANOVA was used to examine whether activity, dyspnoea or fatigue 
changed from baseline and at 12 months (Table 4). There were no significant differences in 
total activity over time [F(3,13)=2.14, n.s.]. In relation to breathlessness (dyspnoea score) this 
decreased over time though the change was not significant [F(3,13)=2.44, n.s.]. There was a 
significant difference for fatigue [F(3,11) = 3.78, p<.05]. Fatigue was highest at baseline 
(M=47.69, SD=13.23) and declined to 42.35 (SD=13.19) at 12 months. Fatigue was lowest at 
6 months. 
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Table 2 SF-36 means, standard deviations and repeated measures ANOVA scores 
SF-36 Scales CKD Sample Normative 
sample 
 
F 
 
p Baseline 3 months 6 months 12 months 
Physical Health   
Physical functioning (PF) 42.7 (28.05) 47.39 (31.14) 54.75 (27.6) 25.45 (13.68) 84.2 (23.3) 3.96 ns 
Role-physical (RP) 41.17 (40.44) 10.85 (4.44) 80.76 (32.52) 63.63 (34.21) 80.9 (34.0) 12.29 p<.05 
Bodily Pain (BP) 70.09 (33.23) 74.43 (26.85) 50.75 (24.13) 48 (20.85) 75.2 (23.7) .084 ns 
General health(GH) 41.66 (18.6) 44.31(21.45) 15.19 (4.5) 14.12 (4.45) 71.9 (20.3) .640 ns 
Physical health summary 56.6 (20.57) 44.58 (15.88) 72.13 (21.79) 56.38 (14.09) 50 (10) - - 
Mental Health   
Vitality (VT) 38.04 (20.65) 46.42 (24.55) 52.61 (24.0) 50.0 (22.06) 60.9 (20.9) 3.93 p<.05 
Social functioning (SF) 61.05 (32.46) 69.04 (28.94) 78.12 (31.38) 75.73 (26.32) 83.3 (22.7) 1.96 ns 
Role-emotional (RE) 63.88 (44.95) 85.0 (29.56) 94.11 (13.09) 86.66 (27.6) 81.3 (33.0) .718 ns 
Mental health (MH) 71.52 (15.24) 74.95 (15.64) 78.85 (21.05) 82.13 (12.9) 74.7 (18.1) 3.62 p<.05 
Mental health summary 60.18 (21.84) 71.57 (17.85) 80.46 (13.98) 73.48 (15.7) 50 (10) - - 
 
ns = not significant 
Table 3 Correlations between SF36 Question 1 (Q1), HAP, Dyspnoea and Fatigue  
 SF-36 Q1 
Baseline 
SF-36 Q1      
3 months 
SF-36 Q1      
6 months 
SF-36 Q1    
12 months 
HAP  
Total activity -.20 .16 .55** .21 
Self-care .11 .37 -.10 -.24 
Personal/household/work .46* .49* .39 .15 
Entertainment/social .44* .54** .58** .47 
Independent exercise .64** .35 .26 .08 
Dyspnoea Score (DS) -.26 -.69** -.63** -.48* 
Fatigue (FSS) -.26 -.51* -.66** -.66** 
 
* p<.05, ** p<.01 
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Table 4 Human Activity Profile, Dyspnoea and Fatigue mean and standard deviation scores  
 Baseline 
M (SD) 
3 months  
M (SD) 
6 months 
 M (SD) 
12 months  
M (SD) 
Normative 
sample 
F p 
HAP scores 
Total activity 43.4 (17.76) 47.95 (20.07) 47.61 (23.68) 48.22 (23.23) 83 2.14 ns 
Self-care 7.31 (1.12) 7.04 (1.77) 7.52  (.98) 7.6 (.77) 7.8 1.30 ns 
Personal/Household work 14.19 (6.7) 15.48 (7.2) 17.19 (6.03) 17.27 (4.52) 24.1 2.99 ns 
p=.07 
Entertainment/Social 7.88 (2.87) 8.04 (2.53) 8.85 (2.61) 9.05 (2.53) 13.6 2.47 ns 
Independent Exercise 6.35 (5.26) 7.3 (5.04) 7.9 (6.17) 8.10 (6.34) 22.2 1.02 ns 
Dyspnoea scores 
Dyspnoea 14.28 (7.61) 13.12 (8.34) 11.59 (7.74) 11.10 (7.90) - 2.14 ns 
FSS Scores 
Fatigue 47.69 (13.18) 47.61 (12.87) 38.7 (17.18) 42.35 (13.19) - 3.78 p<.05 
 
 
Table 5 Correlations between fatigue, physical activity, and breathlessness with SF-36 physical health and mental health over time 
 Baseline 
Physical 
health 
Baseline 
Mental 
health 
Physical 
health 
 3 months 
Mental 
health  
3 months 
Physical 
health  
6 months 
Mental 
health  
6 months 
Physical 
health  
12 months 
Mental 
health  
12 months 
Activity (HAP) .057 .245 .129 -.227 .676** .166 .475* -.407* 
Dyspnoea (DS) -.693** -.461 * -.738*** -.585** -.68** -.239 -.305 -.426* 
Fatigue (FSS) -.812*** -.666** -.525** -.688** -.76*** -.809*** -.557** -.838*** 
 
*p<.05, **p<.001, ***p<.0001 
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Correlations between activity, fatigue and breathlessness with quality of life over time 
Next we wanted to see if activity, breathlessness and fatigue impacted on physical health and 
mental health at different time points. The results of these analyses appear in Table 5. As can 
be seen from Table 5  activity was positively correlated with physical health at both 6 and 12 
months. Activity was negatively correlated with mental health at 12 months (-.407). 
Breathlessness as measured by the Dyspnoea subscale of the HAP was strongly and 
negatively correlated with physical health across all time points except at 12 months (-.305, 
p>.05). Breathlessness was negatively correlated with mental health, with a lower correlation 
between these variables at 6 months (-.239). Increased breathlessness was associated with 
lower mental well-being (-.426). Lastly fatigue was strongly negatively correlated with both 
physical (-.557) and mental health over time (-.838). Higher fatigue levels lead to lower 
HRQoL for both physical health and mental well-being at 12 months.  
 
Age differences over time 
In examining whether there were differences over time on the SF-36 mental and physical 
health components for those aged younger than 65 versus aged over 65 we used mixed 
between-within analyses of variance. There were no significant differences in score changes 
over time for the two age groups for physical health or mental health [F(3,9)=1.78, ns; 
F(3,9)=.256, n.s.].  There were also no age differences in activity [F(3,12)=1.94, n.s.], 
breathlessness [F(3,13)=1.71, n.s.] or fatigue over time [F(3,10)=.388, n.s.]. 
 
These higher order analyses confirm t-test results on the effects of age on the SF-36 physical 
health summary and on the mental health summary. Age differences were only found for SF-
36 mental health at 3 months (t=-2.41, df=14, p<.05). Those younger than 65 years had lower 
emotional well-being (M=63.32, SD=18.41) compared to those aged over 65 (M=82.17, 
SD=10.55). There were no age differences on physical health at any time point. 
 
We were also interested if age was correlated with physical activity, fatigue and 
breathlessness over time. At baseline age was positively correlated with breathlessness 
(r=.536, p<.01); that is older CKD patients reported being more breathless. At 6 months, age 
was negatively correlated with activity (r=-.451, p<.05) (i.e. those over 65 years undertook 
fewer activities) and remained positively correlated with breathlessness (r=.457, p<.05). Age 
was negatively correlated with physical activity (though non-significant) and was positively 
correlated with breathlessness (r=.518, p<.05) at 12 months.  
 
Correlation of Haemoglobin with SF-36 subscales, activity, fatigue and breathlessness 
over time 
 
At baseline haemoglobin (Hb) was not significantly correlated with any of the SF-36 
subscales or the physical and mental health summary components, though the correlation 
with vitality approached significance (r=-.395) as did the correlation with physical 
functioning (r=-.382). However at baseline, Hb (< 100 g/L) was positively correlated with 
physical activity (r=.426, p<.05) and with fatigue (r=.393, p<.05). Breathlessness was 
negatively correlated with activity (r = -.413, p<.05) and positively correlated with fatigue 
(r=.553, p<.01) at baseline. That is, the more breathless CKD patients reported undertaking 
fewer activities and having higher levels of fatigue.  At 3 months Hb was not significantly 
correlated with well-being (SF-36 subscales), activity, fatigue or breathlessness. At 6 months, 
Hb was not significantly correlated with the SF-36 scales. Hb was also not significantly 
correlated with activity, fatigue or breathlessness at 6 months, though less activity was 
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engaged in by those who experienced breathlessness (r=-.579, p<.01). At 12 months Hb was 
negatively correlated with the SF-36 physical health summary (r=-.586, p<.01) and correlated 
-.414 (p<.05) with mental health summary. Hb was not significantly correlated with activity, 
fatigue or breathlessness at 12 months. 
 
DISCUSSION 
A consequence of impaired renal function is the development of persistent, and at times, 
severe anaemia. While anaemia affects normal physiological function, it also causes people to 
experience increased tiredness and reduced ability to undertake daily activities including 
exercise.  We found that people with CKD prior to commencing an ESA reported having 
lower HRQoL when compared to healthy people and this was particularly apparent in the 
physical components. Levels of physical functioning and general health, as well as being able 
to undertake fewer physical roles, contributed to lower HRQoL.  In addition, people in this 
study also indicated that they had lower levels of vitality and experienced more difficulty 
undertaking social functions than healthy people. Mental health aspects associated with 
HRQoL were, however, higher than for healthy people. These findings are consistent with 
Perlman et al. (2005) who found low levels on similar subscales as well as higher mental 
health scores. The reason for higher mental health scores in some people with CKD (i.e. our 
study as well as Perlman et al. 2005) is not known, and further research is warranted. 
 
The capacity to perform routine living chores, and to participate in and enjoy everyday life is 
clearly reduced as a result of having CKD. In this study, activity levels, measured by the 
HAP, also supported the lower physical scores seen with the SF-36. In this study, people 
were only able to perform similar levels of self-care as healthy people but the ability to 
perform personal/household work, being able to undertake social, entertainment or 
independent exercise were substantially less than healthy people. This finding is consistent 
with two other studies of the activity levels of people with CKD using the HAP (Bonner et al. 
2009, Johansen et al. 2010). 
 
Management of anaemia by ESA therapy is believed to lead to a better quality of life for 
people with CKD (Parfrey & Wish 2010). The strength of this study is that we used repeated 
measures over a 12 month period to examine HRQoL as well as levels of fatigue and activity 
following commencement of an ESA. We found that when people with anaemia due to CKD 
are commenced on ESA treatment there are some improvements in HRQoL, breathlessness 
and levels of fatigue over 12 months although their ability to undertake more activities does 
not change.  Our results found a slight improvement in the physical health component of the 
HRQoL measured by the SF-36, although only the role-physical subscale demonstrated 
significant improvement over 12 months.  However there were more improvements in the 
mental health components (vitality & mental health/emotional well-being). In a similar 
longitudinal study involving 34 patients who had recently commenced ESA therapy and who 
completed only the SF-36 at the same time points, Hamilton and Hawley (2006) found 
improvements in several but different subscales of the physical and mental health 
components although most of these improvements were at 3 and 6 months. Leaf and Goldfarb 
(2009), however, suggest that greatest improvements are seen in the HRQoL domains of 
physical symptoms and social functioning. In a recent systematic review of 14 studies, 
Gandra et al. (2010) reported that in people with CKD not yet receiving dialysis (i.e. CKD 
stage 4) who were treated with ESA therapy for anaemia tended to have improvements in the 
physical function and vitality domains associated with HRQoL. 
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In the TREAT study, the largest randomized control trial of anaemia correction with an ESA 
in CKD patients, fatigue scores were statistically improved at 26 weeks following the 
correction of Hb (Pfeffer et al. 2009). In addition Johansen et al. (2011) recently published a 
systematic review of the impact of ESA therapy on fatigue in dialysis patients showing that 
the level of fatigue is reduced as haemoglobin levels are corrected. Our study is consistent 
with these publications with respect to improvements in fatigue levels.  
 
ESA treatment for people with CKD, nevertheless, has improved the potential for higher 
activity levels (Painter et al. 2002, Gandra et al. 2010) however several authors report that 
there has not been a corresponding increase in activity levels (Painter et al. 2011).  The 
findings of the present study seem to concur with the latter at three, six and twelve months 
following commencement of an ESA.  We found that physical functioning, general health, 
social functioning and overall physical health components in the SF-36 as well as total 
activity levels and three out of the four sub-scales from the HAP did not significantly 
improve over time.  
 
There seems to be consistency between the vitality component of the SF-36 which evaluates a 
person’s self-reported feelings of being tired, worn out or full of energy (Ware 2011) and the 
FSS (Krupp et al. 1989).  The present study found a significant improvement in participant 
reported vitality as well as fatigue levels 12 months after commencing an ESA. We also 
found that higher fatigue levels were significantly and negatively correlated with lower 
physical and mental health components associated with HRQoL. Not surprisingly high levels 
of fatigue are experienced by people with CKD which impacts on a person’s quality of life. A 
larger study involving both instruments may be helpful in determining if the FSS should be 
included when using the SF-36 in studies of people with CKD. 
 
Study Limitations 
There are some limitations to this study which must be acknowledged. First, participants 
were from two renal units in Australia which may limit the generalizability of the findings to 
other countries. Second, the instruments rely on self-report which may lead to bias in 
reporting quality of life, the level of activity actually undertaken, and the level of fatigue 
experienced by an individual. Inclusion of the opinion of partners and carers of people with 
CKD may minimize this bias. Lastly and even though the sample size was small, we used 
repeated measures to increase the study’s reliability. The results are suggestive of a better 
quality of life and lower fatigue levels but no significant improvements in levels of activity 
where found. Further studies investigating strategies to enhance activity are clearly needed.   
 
CONCLUSION 
Renal nurses, in CKD clinics and dialysis units, have repeated and frequent contact with 
people with CKD over long periods of time; in some cases over decades. Renal nurses, 
therefore, are in an ideal position to routinely assess fatigue and activity levels and to institute 
timely interventions. Drawing on energy conservation interventions and promoting simple 
physical activity strategies, which are more familiar to nurses who work in rehabilitation 
wards, could be incorporated into routine nursing practice in dialysis units. Renal nurses, 
although having a limited knowledge of rehabilitation, ought to consider innovative and 
efficient ways to provide energy conservation interventions for patients while they attend for 
regular clinic appointments and dialysis treatment. 
 
RELEVANCE FOR NURSING PRACTICE 
There are several important areas for renal nursing practice arising from this study. There is a 
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need for increased focus and assessment to identify and monitor both fatigue and activity 
levels and the impact these seem to have on people’s quality of life. In particular regularly 
assessing a person’s inability to engage in normal self-care, household and, in particular, 
social activities, may give rise to concern about a person’s overall well-being. This could 
assist in instituting interventions for maintaining or increasing everyday activity promptly 
before other physical, social and emotional problems develop and affect a person’s quality of 
life.  Early detection of lowered capacity for and or changes in activity levels would enable 
timely interventions such as referral to allied health staff to optimise independent activity. 
This is particularly important for people who are living at home as optimal independence 
with routine activity is needed, and could assist in lowering the burden on home support 
services. For many people with CKD who opt to receive conservative management (Stage 5), 
continued engagement in routine activity is an important aspect of  maintaining well-being 
and quality of life.  Finally, experimental research by renal nurses is needed to explore the 
effect of innovative nursing interventions specifically targeting simple fatigue reduction 
strategies that maintain levels of activity. 
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